Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard, Benjamin Besse, Harry J.M. Groen et al. · The Lancet Oncology · 2016
Cited by 889 works. doi:10.1016/s1470-2045(16)30146-2
Authors
- David Planchard
- Benjamin Besse
- Harry J.M. Groen
- Pierre-Jean Souquet
- Élisabeth Quoix
- Christina S. Baik
- Fabrice Barlési
- Tae Min Kim
- Julien Mazières
- Silvia Novello
- James R. Rigas
- Allison Upalawanna
- Anthony Michael D'amelio
- Pingkuan Zhang
- Bijoyesh Mookerjee
- Bruce Evan Johnson
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Mutations of the BRAF gene in human cancer
- Cancer statistics, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- A Confidence Interval for the Median Survival Time